Human epidermal growth factor receptor 2 (HER2): Translating the lab to the clinic

Cesar Santa-Maria, Sarika Jain, William J. Gradishar*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


The overexpression/amplification of HER2 has been classically associated with poor outcomes in breast cancer. However, with the advent of targeted therapies this may no longer be the case. A number of agents that are directed at the HER2 molecule or downstream of it have now become available. Evidence from clinical trials seems to suggest that these agents are potent. More importantly, they exert an additive/synergistic effect resulting in improved patient outcomes. In this chapter, we review the available evidence for the use of these agents in metastatic and early breast cancer. We also briefly discuss the mechanisms that have been implicated in the development of resistance to anti-HER2 therapies.

Original languageEnglish (US)
Title of host publicationMolecular Pathology of Breast Cancer
PublisherSpringer International Publishing
Number of pages12
ISBN (Electronic)9783319417615
ISBN (Print)9783319417592
StatePublished - Jan 1 2016


  • HER2
  • Metastatic
  • Neoadjuvant
  • Pertuzumab
  • T-DM1
  • Trastuzumab

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Human epidermal growth factor receptor 2 (HER2): Translating the lab to the clinic'. Together they form a unique fingerprint.

Cite this